Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
TransCode Therapeutics (RNAZ) Ownership Overview
The ownership structure of TransCode Therapeutics (RNAZ) stock is a mix of institutional, retail, and individual investors. , 6.76% is owned by Insiders, and 99.19% is owned by Public Companies and Individual Investors.
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 56,318 | Insider | 6.76% | 411,121 | |
| 6,545 | Institution | 0.79% | 70,621 | |
| 229 | Institution | 0.03% | 2,471 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 229 | Institution | 0.03% | 2,471 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,545 | Institution | 0.79% | 72,060 |
FAQ
Who Owns TransCode Therapeutics (RNAZ)?
Currently, no data Available
What percentage of TransCode Therapeutics (RNAZ) stock is held by institutional investors?
Currently, no data Available
What percentage of TransCode Therapeutics (RNAZ) stock is held by retail investors?
According to the latest TipRanks data, approximately 99.19% of TransCode Therapeutics (RNAZ) stock is held by retail investors.
Who owns the most shares of TransCode Therapeutics (RNAZ)?
Thomas A Fitzgerald owns the most shares of TransCode Therapeutics (RNAZ).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.